NDASUBCUTANEOUSSOLUTION
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
BONSITY (teriparatide) by Alvogen. Approved for parathyroid hormone analog [epc]. First approved in 2019.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BONSITY is a subcutaneous parathyroid hormone analog approved in 2019 for osteoporosis and hypoparathyroidism. It works by mimicking parathyroid hormone to stimulate bone formation and increase bone density. Administered as a solution injection, it represents a pharmacologic approach to rebuilding bone mass in patients at fracture risk.
Peak
BONSITY is at peak commercial stage competing in a moderately competitive osteoporosis market; sustainable revenue and team stability expected near-term.
Mechanism of Action
Pharmacologic Class:
Parathyroid Hormone Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism
Started Apr 2026
36 enrolled
HypoparathyroidismEndocrine System DiseasesParathyroid Diseases
A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)
Started Mar 2026
10 enrolled
Hypoparathyroidism
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
Started Feb 2026
50 enrolled
Hypoparathyroidism
Fracture Recovery for Returning to Duty (Teriparatide STRONG)
Started Dec 2022
183 enrolled
Stress Fracture of Tibia or Fibula
Study and Follow-up of the Clinical Effectiveness and Comparative Safety of Biosimilar Teriparatide in the Management of Postmenopausal or Senile.
Started Jun 2021
188 enrolled
Osteoporosis
Worked on BONSITY at Alvogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.